Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk did not commit to lowering the prices of Ozempic and Wegovi during a Senate hearing on Tuesday, despite repeated pressure from Sen. Bernie Sanders (I-VT), chairman of the Senate Health, Education, Labor and Pensions Committee. Novo Nordisk CEO Lars Fruagaard Jorgensen told senators on Tuesday that pharmacy benefit managers (PBMs), […]
Pfizer moves forward with once-daily weight-loss pill to compete with Wegovy
Pfizer, which discontinued a twice-daily version of the drug late last year, said Thursday that an improved, once-daily version of its weight-loss drug danugliplon will move into clinical trials later this year. The new drug is one of a generation of second-generation weight-loss drugs being developed by companies including Eli Lilly and Novo Nordisk that […]
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
Hims & Hers Health CEO and co-founder Andrew Dudum talks about the telemedicine company’s weight loss platform on The Claman Countdown. Health platform Hims & Hers Health Inc. announced Monday that it is rolling out an injectable weight-loss drug at a fraction of the price of competitors Wegovy and Ozempic. Hims & Hers says its […]
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says – CNBC
More plans covering Wegobee’s costs could put pressure on Medicare’s budget. According to KFF, if just 10% of the eligible population (estimated at 360,000 people) used the drug for a year, the program’s prescription drug plans could cost an additional $2.8 billion net. Under new guidance issued in March, Medicare Part D plans require patients […]
1 in 4 Medicare beneficiaries with obesity could get Wegovy despite coverage ban
An estimated 3.6 million Medicare beneficiaries could have access to Wegovy after the Food and Drug Administration (FDA) approved a drug that reduces the risk of accidents related to cardiovascular disease. KFF’s analysis found that of the 13.7 million Medicare enrollees diagnosed with obesity, 3.6 million, or roughly 1 in 4, had a diagnosis of […]
Medicare plans can cover Wegovy — but not for weight loss
Although the program does not cover the drug for weight loss purposes, the decision could open up access and provide a potential path for future efforts. The Centers for Medicare and Medicaid Services (CMS) has issued guidance for Medicare Part D plans run by private companies to cover obesity drugs to beneficiaries as long as […]
Medicare can now cover Wegovy for more senior citizens – CNN
Amanda Andrade Rose/Associated Press Medicare Part D drug plans may cover Wegovy for older adults who have heart disease and are obese or overweight. CNN — Medicare could begin covering Wegoby for certain seniors and other beneficiaries with a history of heart disease after the U.S. Food and Drug Administration approved drugmaker Novo Nordisk’s application. […]
Weight-loss drug Wegovy approved by FDA to cut heart attack, stroke risk
Wegoby, the popular weight loss drug that has helped millions of Americans lose weight, can now be used to reduce the risk of stroke, heart attack, and other serious cardiovascular disease in overweight or obese patients. I did. Federal regulators announced Friday.. The Food and Drug Administration has approved label changes requested by drug company […]
Novo Nordisk parent buys US drug firm for $16.5bn to expand Wegovy supply | Pharmaceuticals industry
The explosion in demand for the weight-loss drug Wegoby has prompted the holding company of its maker, Novo Nordisk, to buy the US-based drug giant for $16.5 billion ($12.70) and end its production capacity. Novo Holdings has acquired New Jersey-based pharmaceutical company Catalent, which it plans to immediately sell three of its locations in the […]
Ozempic and Wegovy maker Novo Nordisk now worth $500B
The soaring popularity of weight-loss drugs Ozempic and Wigovy has pushed parent company Novo Nordisk’s valuation past the $5 trillion threshold, according to the report. The Danish drug company, which originally sold the drug as a treatment for diabetes, was valued at $506 billion. According to CNBCanalyzed data from the London Stock Exchange Group. Novo […]